Amylin, Onglyza, and Farxiga — Business sale royalty expense
Bristol-Myers Squibb Amylin, Onglyza, and Farxiga — Business sale royalty expense remained flat by 0.0% to $24.00M in Q4 2024 compared to the prior quarter. Year-over-year, this metric declined by 2.0%, from $24.50M to $24.00M. Over 2 years (FY 2022 to FY 2024), Amylin, Onglyza, and Farxiga — Business sale royalty expense shows a downward trend with a -8.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
A decrease in royalty expense generally indicates the expiration of contractual obligations or a decline in sales of the associated divested products, while an increase suggests sustained or growing revenue from those assets.
Detailed definition
This metric represents the ongoing royalty obligations incurred by the company resulting from the divestiture or licensi...
Peer comparison
Similar to contingent consideration or earn-out payments found in other pharmaceutical divestiture agreements, where companies retain a portion of revenue or pay royalties to former owners or partners.
bmy_segment_amylin_onglyza_and_farxiga_business_sale_royalty_expenseHistorical Data
| FY'22 | FY'23 | FY'24 | |
|---|---|---|---|
| Value | $114.00M | $98.00M | $96.00M |
| YoY Change | — | -14.0% | -2.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's amylin, onglyza, and farxiga — business sale royalty expense?
- Bristol-Myers Squibb (BMY) reported amylin, onglyza, and farxiga — business sale royalty expense of $24.00M in Q4 2024.
- How has Bristol-Myers Squibb's amylin, onglyza, and farxiga — business sale royalty expense changed year-over-year?
- Bristol-Myers Squibb's amylin, onglyza, and farxiga — business sale royalty expense decreased by 2.0% year-over-year, from $24.50M to $24.00M.
- What is the long-term trend for Bristol-Myers Squibb's amylin, onglyza, and farxiga — business sale royalty expense?
- Over 2 years (2022 to 2024), Bristol-Myers Squibb's amylin, onglyza, and farxiga — business sale royalty expense has grown at a -8.2% compound annual growth rate (CAGR), from $114.00M to $96.00M.
- What does amylin, onglyza, and farxiga — business sale royalty expense mean?
- The recurring royalty costs paid to third parties based on sales of previously divested or licensed pharmaceutical products.